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Background
 
Thrombin has a pivotal role in the 
pathogenesis of acute coronary thrombosis. We 
compared the clinical efficacy of a potent, direct 
thrombin inhibitor, recombinant hirudin, with that of 
heparin (an indirect antithrombin agent) in patients 
with unstable angina or acute myocardial infarction.
 
Methods
 
At 373 hospitals in 13 countries, 12,142 
patients with acute coronary syndromes were ran-
domly assigned to 72 hours of therapy with either in-
travenous heparin or hirudin. Patients were stratified 
according to the presence of ST-segment elevation 
on the base-line electrocardiogram (4131 patients) or 
its absence (8011 patients), with the latter character-
istic considered to indicate unstable angina or non–
Q-wave myocardial infarction.
 
Results
 
At 24 hours, the risk of death or myocar-
dial infarction was significantly lower in the group 
assigned to hirudin therapy than in the group 
assigned to heparin (1.3 percent vs. 2.1 percent, 
P
 

 
0.001). The primary end point of death or nonfa-
tal myocardial infarction or reinfarction at 30 days 
was reached in 9.8 percent of the heparin group as 
compared with 8.9 percent of the hirudin group 
(odds ratio for the risk of the end point in the hirudin 
group, 0.89; 95 percent confidence interval, 0.79 to 
1.00; P
 

 
0.06). The predominant effect of hirudin 
was on myocardial infarction or reinfarction and was 
not influenced by ST-segment status. There were no 
significant differences in the incidence of serious or 
life-threatening bleeding complications, but hirudin 
therapy was associated with a higher incidence of 
moderate bleeding (8.8 percent vs. 7.7 percent, 
P
 

 
0.03).
 
Conclusions
 
For acute coronary syndromes, re-
combinant hirudin provided a small advantage, as 
compared with heparin, principally related to a re-
duction in the risk of nonfatal myocardial infarction. 
The relative therapeutic effect was more pronounced 
early (at 24 hours) but dissipated over time. The 
small benefit was consistent across the spectrum of 
acute coronary syndromes and was not associated 
with a greater risk of major bleeding complications. 
(N Engl J Med 1996;335:775-82.)
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N recent years, the common underlying patho-
physiology of acute coronary syndromes in-
volving the fissure or rupture of atherosclerotic
plaques with mural or occlusive thrombus has
been increasingly recognized.
 
1-4
 
 Therapy for the var-
ious acute coronary syndromes (including unstable
angina and nontransmural and transmural myocar-
I
 
dial infarction) is remarkably similar, consisting of
intravenous heparin, aspirin, and anti-ischemic med-
ications; the only important difference involves the
use of thrombolytic therapy, which is restricted to
patients with ST-segment elevation.
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 Thrombin is
a key component of the pathophysiology of acute
coronary syndromes. Thrombin plays a pivotal part
in coronary-artery thrombosis by promoting platelet
aggregation, engendering its own formation by means
of an autocatalytic feedback loop, and catalyzing the
cross-linkage of the fibrin clot. Although heparin is
the mainstay of antithrombin therapy, it works indi-
rectly, requires antithrombin III as a cofactor, and is
not effective against thrombin that is already bound
to the fibrin clot. Furthermore, heparin can be
readily inactivated by platelet factor 4 or plasma pro-
teins, its effects vary considerably within and be-
tween patients, and it leads to thrombocytopenia in
5 to 15 percent of patients.
 
9-13
 
 The prototypical di-
rect inhibitor of thrombin is hirudin, a peptide of 65
amino acids that is derived from the saliva of the me-
dicinal leech (
 
Hirudo medicinalis
 
). In pilot trials of
patients with unstable angina and acute myocardial
infarction, hirudin has shown promise.
 
7-9
 
 We de-
signed the current study after a trial of 2565 patients
showed that high doses of heparin and hirudin were
associated with an unacceptable rate of bleeding
complications.
 
14
 
 We compared the clinical effective-
ness of hirudin with that of heparin in patients with
all types of acute coronary syndromes.
 
METHODS
 
Patient Population
 
Patient enrollment began May 19, 1994, and was completed
October 17, 1995. The entry criteria consisted of chest discom-
fort within the previous 12 hours associated either with transient
or persistent ST-segment elevation or depression of more than 0.5
mm or with persistent, definite T-wave inversion of more than
1 mm. Patients were excluded if they were taking warfarin at the
time of enrollment or if they had active bleeding, a history of
stroke, a contraindication to heparin therapy or renal insufficiency
(serum creatinine, 
 

 
2.0 mg per deciliter [177 
 
m
 
mol per liter], a
relative contraindication to hirudin therapy), a systolic blood
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pressure of more than 200 mm Hg, or a diastolic blood pressure
of more than 110 mm Hg. Women of childbearing potential were
excluded. If a patient was enrolled and was subsequently found
to have a serum creatinine concentration of more than 2.0 mg
per deciliter at base line, the study-drug infusion was discontin-
ued. The objective was to enroll a representative cross-section of
patients with acute coronary syndromes, with a target of 4000 pa-
tients with ST-segment elevation and 8000 patients with no
ST-segment elevation. In patients with ST-segment elevation, the
decision to use thrombolytic therapy was made by the attending
physician. Thrombolytic therapy consisted of either streptokinase
or a regimen of accelerated tissue plasminogen activator (t-PA) in
which t-PA is infused rapidly over a period of 1
 
1
 
⁄
 
2
 
 hours so that
two thirds of the dose is given in the first 30 minutes.
 
15
 
The protocol called for the infusion of the study medication
for a minimum of three and a maximum of five days, at the dis-
cretion of the attending physician. Each patient received either
heparin and hirudin placebo or hirudin and heparin placebo on a
double-blind basis. Hirudin was initially given in a bolus dose of
0.1 mg per kilogram of body weight intravenously, followed by a
continuous infusion of 0.1 mg per kilogram per hour. The de-
sulfated form of recombinant hirudin (desirudin, Ciba–Geigy,
Summit, N.J.) was used. Heparin was initially given in a bolus
dose of 5000 U intravenously, followed by a continuous infusion
of 1000 U per hour.
The activated partial-thromboplastin time was determined be-
fore the study drug was infused, at 6 hours, 12 hours, and 24 hours,
and then a minimum of once a day during its administration. The
activated partial-thromboplastin time was adjusted with the use
of a standard nomogram to maintain the value between 60 and
85 seconds.
 
16
 
 In patients undergoing coronary intervention dur-
ing the administration of the study drug, specific guidelines al-
lowed the use of a bolus infusion of heparin or placebo and hiru-
din or placebo to achieve an activated clotting time of at least 300
to 350 seconds and preserve the double-blind nature of the study.
 
End Points
 
The primary composite end point was death or nonfatal myo-
cardial infarction (or reinfarction) in the first 30 days of follow-
up. Myocardial infarction and reinfarction have been defined
previously
 
14
 
 and were classified by members of the clinical-events
committee, who were unaware of the patients’ treatment assign-
ments.
Bleeding complications were categorized according to previous
definitions.
 
14,15
 
 Severe or life-threatening bleeding was defined as
intracranial hemorrhage or bleeding that caused hemodynamic
compromise requiring intervention. Moderate bleeding was de-
fined as bleeding that required transfusion but was not associated
with any hemodynamic compromise.
 
Invasive Cardiologic Procedures
 
Coronary angiography, percutaneous coronary revasculariza-
tion, and coronary-artery bypass surgery were discouraged for the
duration of the study-drug infusion unless there was evidence of
recurrent ischemia. For patients who were undergoing elective
coronary-artery bypass surgery, it was recommended that the
study drug be stopped six to eight hours before surgery, with
heparin therapy initiated if indicated on an open basis. In cases of
emergency bypass surgery, unblinding of study drug was permit-
ted to avoid inappropriate use of protamine and facilitate the con-
trol of hemostasis.
 
Statistical Analysis
 
Interim analyses were planned for the primary end point after
each increment of 25 percent of the planned number of patients
had been enrolled; they were actually performed after data on
the primary end point were available for 2731, 5946, and 9627
patients. To monitor the statistical significance of interim differ-
ences between treatments, the method of DeMets and Ware was
used.
 
17
 
*For continuous variables, the median values are provided, with the 25th and 75th percentiles giv-
en in parentheses. CABG denotes coronary-artery bypass grafting, and PTCA percutaneous translu-
minal coronary angioplasty.
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HIRUDIN
 
 
(
 
N
 

 
6069)
 
HEPARIN
 
 
(
 
N
 

 
6073)
 
ELEVATED
 
 
(
 
N
 

 
4131)
 
NOT
 
 
 
ELEVATED
 
 
(
 
N
 

 
8011)
Age (yr) 65 (55, 73) 65 (56, 73) 63 (53, 71) 66 (57, 73)
Female sex (%) 30 30 24 33
Systolic blood pressure
(mm Hg)
135 (120, 150) 135 (120, 150) 130 (115, 148) 139 (120, 151)
Diastolic blood pressure
(mm Hg)
80 (70, 90) 80 (70, 90) 80 (70, 90) 80 (70, 90)
Heart rate (beats/min) 74 (64, 86) 74 (64, 85) 74 (64, 86) 74 (64, 85)
Killip class (%)
I
II
III or IV
88
10
2
87
12
1
88
11
1
88
11
1
Prior myocardial infarction (%) 27 27 17 32
Prior CABG (%) 9 10 5 12
Prior PTCA (%) 9 8 6 11
Hypertension (%) 44 47 40 48
Diabetes (%) 17 19 16 19
Hypercholesterolemia (%) 39 39 36 41
Current smoker (%) 32 31 41 27
Weight (kg) 76 (68, 86) 76 (68, 86) 77 (68, 86) 76 (67, 86)
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The case report was fully documented for 10 percent of pa-
tients, and the documentation process included at least one visit
by a monitor to the study sites. In addition, all in-hospital deaths,
myocardial infarctions and reinfarctions, strokes, life-threatening
bleeding complications, and unanticipated, serious life-threaten-
ing adverse events were reviewed. Thus, the medical records of 20
percent of the patients were reviewed.
Statistical analyses included all randomized patients according to
the intention-to-treat principle. For the full cohort of patients, the
Cochran–Mantel–Haenszel test was used to assess differences in
the treatment groups with respect to the primary end point,
 
18
 
 with
stratification according to whether the patients presented with or
without ST-segment elevation. This test was also used to analyze
discrete secondary end points. In the group without ST-segment
elevation, the conventional chi-square test was used to compare
treatment-related differences in the primary end point and discrete
secondary end points. For secondary end points involving contin-
uous variables, treatments were compared with use of the nonpara-
metric Wilcoxon rank-sum test. All P values are two-sided.
 
RESULTS
 
A total of 12,142 patients were enrolled in 373
hospitals in 13 countries (see the Appendix): 4131
had ST-segment elevation, and 8011 did not. The
base-line characteristics of the entire cohort accord-
ing to treatment assignment and ST-segment status
are given in Table 1. As compared with patients with
ST-segment elevation, patients without ST-segment
elevation were more likely to be older, to be female,
to have had prior cardiac disease, and to have an in-
creased prevalence of risk factors for cardiac disease.
The study drug was actually administered to 98.4
percent of patients, with no difference between
treatment groups in the percentage who actually re-
ceived treatment; in both groups treatment was ini-
tiated a median of 0.5 hour (25th and 75th percen-
tiles, 0.3 and 0.8) after randomization. The mean
(
 

 
SD) duration of therapy was 75
 

 
29 hours in the
hirudin group and 75
 

 
29 hours in the heparin
group. Treatment was continued for at least 72
hours in 70.2 percent of the patients in the hirudin
group and 70.6 percent of the patients in the hepa-
rin group. For the patients in whom treatment was
stopped early (before 72 hours), the reasons were as
follows: the need for procedures in 26 percent of pa-
tients, physician preference in 25 percent, bleeding
in 12 percent, transfer to another hospital in 7 per-
cent, death in 6 percent, misdiagnosis in 6 percent,
an adverse event in 3 percent, and miscellaneous or
unknown reasons in the remaining 15 percent.
Among the patients with ST-segment elevation, 74
percent received thrombolytic therapy, consisting of
t-PA in 70 percent of patients and streptokinase in
30 percent. The median length of time from the on-
set of thrombolytic therapy to the initiation of treat-
ment with the study drug was 35 minutes in the
hirudin group (25th and 75th percentiles, 15 and
68, respectively) and 35 minutes in the heparin
group (25th and 75th percentiles, 15 and 71). The
relevant adjunctive medications given and proce-
dures performed in the trial are summarized in Table
2. Figure 1 shows the effects of hirudin and heparin
on the activated partial-thromboplastin time. During
the infusion, 94.6 percent of the patients assigned to
heparin required an adjustment in the dosage, as
compared with 71.5 percent of those assigned to
hirudin (P
 

 
0.001).
The incidence of death or myocardial infarction at
30 days — the primary composite end point — is
given in Table 3. After 24 hours of therapy, the risk
of death or myocardial infarction was significantly
lower in the group assigned to hirudin (1.3 percent,
vs. 2.1 percent for heparin; odds ratio, 0.61; 95 per-
cent confidence interval, 0.46 to 0.81; P
 

 
0.001).
The difference in this risk between groups was also
significant 48 hours after the initiation of therapy
(2.3 percent and 3.1 percent, respectively; odds ra-
tio, 0.73; 95 percent confidence interval, 0.59 to
0.91; P
 

 
0.001). Figure 2 shows the Kaplan–Meier
estimates of the risk of death or myocardial infarc-
tion in the first 72 hours after randomization.
The 30-day event rates for the primary end points
of death or nonfatal myocardial infarction for all pa-
tients, patients with ST-segment elevation, and pa-
tients without ST-segment elevation are presented in
Figure 3. At 30 days 9.8 percent of the heparin
group had reached the primary end point, as com-
pared with 8.9 percent of the hirudin group (odds
ratio, 0.89; 95 percent confidence interval, 0.79 to
1.00; P
 

 
0.06). This effect of hirudin was not influ-
enced by ST-segment status (Table 3). However,
 
*ACE denotes angiotensin-converting enzyme, CABG coronary-artery
bypass grafting, and PTCA percutaneous transluminal coronary angio-
plasty.
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HIRUDIN HEPARIN ELEVATED
NOT
 
 
 
ELEVATED
 
percent
 
Aspirin 97 98 98 97
Nitrates
Oral or topical
Intravenous
84
77
84
79
78
82
88
76
Calcium-channel blockers 52 51 37 59
Beta blockers
Intravenous
Oral
17
73
17
72
25
73
13
72
ACE inhibitor 33 34 39 32
Coronary arteriography 58 57 59 57
PTCA 22 23 31 19
CABG 12 11 8 14
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there were no significant differences between hiru-
din and heparin in the incidence of other clinical
events, such as recurrent ischemia, heart failure, ar-
rhythmias, or cardiogenic shock. The secondary com-
posite end point of death, myocardial infarction, or
disability from stroke was reached in 9.2 percent of
the hirudin group and 10.2 percent of the heparin
group (P
 

 
0.07).
The bleeding complications and incidence of
stroke in the treatment groups are shown in Table 4.
Although it was not a statistically significant differ-
ence, there was a higher incidence of intracranial hem-
orrhage among patients without ST-segment elevation
who were treated with hirudin, as compared with
those treated with heparin (0.2 percent [6 events] vs.
0.02 percent [1 event]), and a higher overall rate of
moderate bleeding in the group treated with hirudin
(8.8 percent vs. 7.7 percent, P
 

 
0.03).
 
DISCUSSION
 
In this trial of acute coronary syndromes, we ob-
served a high (9.4 percent) event rate for the com-
posite end point of death or myocardial infarction at
30 days despite a therapeutic approach that included
the use of aspirin, heparin, beta-blockers, nitrates,
and calcium-channel blockers. Although patients
with ST-segment elevation were younger, were more
likely to be male, and had fewer cardiac risk factors
and a lower incidence of prior ischemic heart disease
than patients without ST-segment elevation, they
had a higher risk of death at 30 days (6.1 percent vs.
3.8 percent) and a similar rate of myocardial infarc-
tion (5.5 percent vs. 6.0 percent), most cases of
which were actually reinfarctions. Although many of
the demographic factors were suspected to differ be-
tween patients with ST-segment elevation and pa-
tients without ST-segment elevation after myocar-
dial infarction or acute ischemia, our results establish
that the latter group has a greater number of char-
acteristics that are associated with more advanced
coronary artery disease.
We compared the effect of heparin with that of a
direct thrombin inhibitor, recombinant hirudin, which
is a more potent anticoagulant.
 
7-10
 
 Mechanistically,
hirudin has the advantage of affecting clot-bound
thrombin, not requiring any cofactors, and not
being inactivated by plasma proteins or platelet fac-
tor 4. Although the hypothesis that potent, direct
inhibition of thrombin would improve clinical out-
comes appears valid on the basis of our observations
 
Figure 1.
 
 Activated Partial-Thromboplastin Times after 6, 12,
and 24 Hours of Treatment with Intravenous Hirudin or Heparin.
In each box plot the lower and upper ends represent the 25th
and 75th percentiles, respectively, and the horizontal line rep-
resents the median.
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TABLE 3. THE INCIDENCE OF THE PRIMARY CLINICAL END POINTS AT 30 DAYS
IN PATIENTS WITH ACUTE CORONARY SYNDROMES.
GROUP HIRUDIN HEPARIN ODDS RATIO (95% CI)*
P 
VALUE
NO. OF 
PATIENTS %
NO. OF 
PATIENTS %
All patients
Death
Myocardial infarction
Death or myocardial infarction
6069
4.5
5.4
8.9
6073
4.7
6.3
9.8
0.95 (0.80–1.13)
0.86 (0.74–1.00)
0.89 (0.79–1.00)
0.58
0.04
0.058
Patients with ST-segment elevation
Death
Myocardial infarction
Death or myocardial infarction
2075
5.9
5.0
9.9
2056
6.2
6.0
11.3
0.94 (0.73–1.2)
0.82 (0.63–1.07)
0.86 (0.70–1.05)
0.64
0.15
0.13
Patients without ST-segment elevation
Death
Myocardial infarction
Death or myocardial infarction
3994
3.7
5.6
8.3
4017
3.9
6.4
9.1
0.96 (0.76–1.21)
0.87 (0.73–1.05)
0.90 (0.78–1.06)
0.72
0.152
0.22
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at 30 days, the extent of the benefit was small (11
percent reduction in risk) and of marginal statistical
significance. However, hirudin was associated with a
significant and substantial reduction in the risk of
death or myocardial infarction at 24 and 48 hours.
The small benefit at 30 days was similar in patients
with ST-segment elevation and in those without
ST-segment elevation.
Our results are discrepant with those of the recent
Thrombolysis in Myocardial Infarction (TIMI) 9 tri-
al, which indicated no advantage of hirudin over
heparin for patients treated with thrombolytic ther-
apy.19 There was a similar proportionate reduction
(14 percent) in reinfarction with hirudin in that tri-
al, but the mortality rate with hirudin therapy was
slightly higher than that with heparin therapy (6.1
percent vs. 5.1 percent; odds ratio, 1.21; 95 percent
confidence interval, 0.88 to 1.65). The only con-
spicuous differences between the TIMI 9 trial and
our study were a longer interval from randomization
to the initiation of the study drug (median, 44 vs.
35 minutes), a longer duration of treatment (96 vs.
75 hours), and fewer patients over 75 years of age
(11 percent vs. 18 percent). Accordingly, the reason
for the lack of concordance between the two trials
remains unclear. 
The reasons for the borderline evidence of the in-
cremental efficacy of hirudin over heparin in the cur-
rent trial are also uncertain. Among the possibilities
are an inadequate dose of hirudin, an insufficient du-
ration of treatment, or the lack of durability of the
effects of hirudin. In the Global Use of Strategies to
Open Occluded Coronary Arteries (GUSTO) IIa tri-
al, a much higher dose of recombinant hirudin was
used (a bolus dose of 0.6 mg per kilogram followed
by an infusion of 0.2 mg per kilogram per hour), but
the bleeding-related side effects could not be toler-
ated and the incidence of intracerebral hemorrhage
among patients receiving thrombolytic therapy was
excessive (1.6 percent).14 Even among patients who
did not receive thrombolytic therapy, there was a 0.5
percent incidence of hemorrhagic stroke in the group
given hirudin as compared with an incidence of
0 percent in the group given heparin. There was no
Figure 2. Kaplan–Meier Estimate of the Probability of Death or
Myocardial Infarction or Reinfarction during the First 72 Hours
after Randomization, According to Treatment Assignment.
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Figure 3. Kaplan–Meier Estimate of the Probability of Death or
Myocardial Infarction or Reinfarction in All Patients (Panel A),
Those with ST-Segment Elevation (Panel B), and Those without
ST-Segment Elevation (Panel C).
Unless otherwise indicated, the P value was determined by the
Cochran–Mantel–Haenszel test.
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indication of improved efficacy with high doses of
both hirudin and heparin: the rate of death or myo-
cardial infarction was 11.7 percent in the hirudin
group and 11.0 percent in the heparin group. In a
trial involving patients with unstable angina and
non–Q-wave myocardial infarction who were given a
similar recombinant hirudin at a dose intermediate
between that used in GUSTO IIa and the current tri-
al (a bolus dose of 0.4 mg per kilogram followed by
an infusion of 0.15 mg per kilogram per hour), the
incidence of bleeding complications was twice as
high in the hirudin group as in the heparin group.20
Although with the doses of hirudin used in the cur-
rent trial (a bolus of 0.1 mg per kilogram and an in-
fusion of 0.1 mg per kilogram per hour) there was
no worrisome increase in major bleeding complica-
tions, there was an increased incidence of intracere-
bral hemorrhage (1 per 1000 patients treated) and a
higher rate of moderate bleeding. Collectively, these
data suggest that there is a narrow therapeutic win-
dow for treatment with recombinant hirudin and
that the administration of doses higher than those
tested in the current trial may increase the risk of
bleeding complications without substantially improv-
ing efficacy. A longer infusion of hirudin might in-
crease efficacy, but the lack of benefit in the TIMI 9
trial, in which therapy was administered an average of
30 percent longer than in the present study, makes
this possibility less likely.
Other factors besides the dose or duration of
treatment may explain the borderline results. All the
beneficial effects of hirudin were evident within the
first 24 hours. Beyond that point, the event-rate
curves neither diverged nor converged. This failure
to prevent events beyond 24 hours may be attribut-
ed either to rebound hypercoagulability after the in-
fusion of thrombin inhibitors was stopped or to a
lack of “passivation” of the arterial surface that con-
tinued to allow the formation of platelet throm-
bus.21-24 A similar lack of durability of the effect of
thrombin inhibitors has been noted in three recent
trials.25-27 Serial assays of prothrombin fragment
(F 1.2) during hirudin therapy28-30 have confirmed
the inability of hirudin to block the generation of
thrombin. The consequent accumulation of throm-
bin may have detracted from the ability of hirudin
to inhibit the activity of thrombin and thus reduce
ischemia.
Our data call into question the existence of a piv-
otal role for thrombin in acute coronary thrombosis.
In contrast, recent trials have provided evidence of
the high efficacy of blockade of platelet glycoprotein
IIb/IIIa in acute coronary syndromes.21-23 Although
thrombin is an important agonist of platelet aggre-
gation, it represents 1 pathway of platelet activation
among nearly 100.24 At appropriate doses, an effec-
tive platelet glycoprotein IIb/IIIa inhibitor, which
modulates the final common pathway of aggrega-
tion, blocks virtually all these agonists. In the future,
the combination of direct thrombin inhibition and
blockade of platelet glycoprotein IIb/IIIa, which
has shown promise in experimental models,31 may
prove to have particular therapeutic value.
Hirudin led to a very consistent anticoagulant ef-
fect over time, independently of the use of throm-
bolytic therapy, a feature that represents a practical
advantage. Heparin not infrequently engenders an
immune thrombocytopenia, which can result in se-
rious thrombotic complications.32 However, heparin,
which is inexpensive, performed quite well as an an-
tithrombin agent in the current trial and should still
be regarded as the standard therapy. Recombinant
hirudin resulted in a small but demonstrable and
consistent effect, especially on the rate of reinfarc-
tion, in the group of patients with acute coronary
syndromes as a whole. Whether the practical advan-
tage of hirudin, its small clinical benefit, and its
somewhat increased bleeding risk will limit its use to
select patients with acute coronary syndromes re-
quires independent cost–benefit analysis.
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*This category includes stroke from any cause.
TABLE 4. THE INCIDENCE OF BLEEDING COMPLICATIONS
AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROMES.
GROUP HIRUDIN HEPARIN P VALUE
NO. OF 
PATIENTS %
NO. OF 
PATIENTS %
All patients
Severe bleeding
Moderate bleeding
Transfusion
Intracranial hemorrhage
Stroke*
6069
1.2
8.8
9.7
0.3
0.9
6073
1.1
7.7
8.6
0.2
0.8
0.49
0.03
0.04
0.24
0.43
Patients with ST-segment elevation
Severe bleeding
Moderate bleeding
Transfusion
Intracranial hemorrhage
Stroke*
2075
1.1
8.6
9.0
0.5
1.3
2056
1.5
7.8
8.9
0.4
0.8
0.20
0.32
0.93
0.84
0.14
Patients without ST-segment 
elevation
Severe bleeding
Moderate bleeding
Transfusion
Intracranial hemorrhage
Stroke*
3994
1.3
8.9
10.2
0.2
0.8
4017
0.9
7.7
8.4
0.02
0.7
0.06
0.06
0.01
0.06
0.72
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